Comparative Pharmacology
Head-to-head clinical analysis: SOSOL versus SOXAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOSOL versus SOXAZOLE.
SOSOL vs SOXAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces myocardial oxygen demand by decreasing heart rate, contractility, and blood pressure.
Soxazole is a synthetic antibacterial agent that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby interfering with nucleic acid production.
120-240 mg orally once daily; initial dose 120 mg.
500 mg orally every 6 hours for 7-14 days.
None Documented
None Documented
12-15 hours (terminal); clinically significant for once-daily dosing
Terminal elimination half-life is 8-12 hours in adults; prolonged to 15-20 hours in renal impairment (CrCl <30 mL/min).
Clinical Note
moderateSulfisoxazole + Gatifloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfisoxazole + Rosoxacin
"Sulfisoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfisoxazole + Trovafloxacin
"Sulfisoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfisoxazole + Nalidixic acid
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Renal excretion of unchanged drug (70-80%) and hepatic metabolism with fecal elimination (15-20%); biliary excretion accounts for minor route (<5%).
Category C
Category C
Sulfonamide antibiotic
Sulfonamide antibiotic
"Sulfisoxazole may increase the hypoglycemic activities of Nalidixic acid."